First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Clarisse Audigier-Valette, Bogdan Zurawski, Helena Linardou, Gregory A. Otterson, Pamela Salman, Makoto Nishio, Emmanuel de la Mora Jimenez, Krysztof Lesniewski-Kmak, István Albert, Samreen Ahmed, Konstantinos Syrigos, John R. Penrod, Yong Yuan, Steven I. Blum, Faith E. Nathan, Xiaowu Sun, Alejandro Moreno-Koehler, Fiona Taylor, Kenneth John O'Byrne

Open source

DOI: 10.1016/j.jtho.2020.12.019
Published: 2021-04
Container: Journal of Thoracic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2020.12.019,
  title = {First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1\% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1},
  author = {Martin Reck and Tudor-Eliade Ciuleanu and Jong-Seok Lee and Michael Schenker and Clarisse Audigier-Valette and Bogdan Zurawski and Helena Linardou and Gregory A. Otterson and Pamela Salman and Makoto Nishio and Emmanuel de la Mora Jimenez and Krysztof Lesniewski-Kmak and István Albert and Samreen Ahmed and Konstantinos Syrigos and John R. Penrod and Yong Yuan and Steven I. Blum and Faith E. Nathan and Xiaowu Sun and Alejandro Moreno-Koehler and Fiona Taylor and Kenneth John O'Byrne},
  year = {2021},
  journal = {Journal of Thoracic Oncology},
  doi = {10.1016/j.jtho.2020.12.019},
  url = {https://doi.org/10.1016/j.jtho.2020.12.019}
}

RIS

TY  - JOUR
TI  - First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
AU  - Martin Reck
AU  - Tudor-Eliade Ciuleanu
AU  - Jong-Seok Lee
AU  - Michael Schenker
AU  - Clarisse Audigier-Valette
AU  - Bogdan Zurawski
AU  - Helena Linardou
AU  - Gregory A. Otterson
AU  - Pamela Salman
AU  - Makoto Nishio
AU  - Emmanuel de la Mora Jimenez
AU  - Krysztof Lesniewski-Kmak
AU  - István Albert
AU  - Samreen Ahmed
AU  - Konstantinos Syrigos
AU  - John R. Penrod
AU  - Yong Yuan
AU  - Steven I. Blum
AU  - Faith E. Nathan
AU  - Xiaowu Sun
AU  - Alejandro Moreno-Koehler
AU  - Fiona Taylor
AU  - Kenneth John O'Byrne
PY  - 2021
JO  - Journal of Thoracic Oncology
DO  - 10.1016/j.jtho.2020.12.019
UR  - https://doi.org/10.1016/j.jtho.2020.12.019
ER  -

APA

Reck, M., Ciuleanu, T., Lee, J., Schenker, M., Audigier-Valette, C., Zurawski, B., Linardou, H., Otterson, G. A., Salman, P., Nishio, M., Jimenez, E. D. L. M., Lesniewski-Kmak, K., Albert, I., Ahmed, S., Syrigos, K., Penrod, J. R., Yuan, Y., Blum, S. I., Nathan, F. E., Sun, X., Moreno-Koehler, A., Taylor, F., & O'Byrne, K. J. (2021). First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.12.019

Source records

crossref · retrieved 2026-09-26T17:06:57.265Z